Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Gains from Sales and Divestitures (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Gains from Sales and Divestitures for 13 consecutive years, with $46371.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 6.36% to $46371.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $46371.0, a 6.36% decrease, with the full-year FY2025 number at $46371.0, down 6.36% from a year prior.
  • Gains from Sales and Divestitures was $46371.0 for Q4 2025 at Lemaitre Vascular, down from $49521.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $49521.0 in Q4 2024 to a low of $45489.0 in Q4 2022.
  • A 4-year average of $47695.2 and a median of $47885.5 in 2023 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: increased 8.6% in 2023, then decreased 6.36% in 2025.
  • Lemaitre Vascular's Gains from Sales and Divestitures stood at $45489.0 in 2022, then rose by 8.6% to $49400.0 in 2023, then grew by 0.24% to $49521.0 in 2024, then dropped by 6.36% to $46371.0 in 2025.
  • Per Business Quant, the three most recent readings for LMAT's Gains from Sales and Divestitures are $46371.0 (Q4 2025), $49521.0 (Q4 2024), and $49400.0 (Q4 2023).